3
Clinical Trials associated with Alprostadil liposome(CSPC Zhongqi)A Multicenter, Randomized, Open-label Phase II Clinical Trial Evaluating Alprostadil Liposomal Injection in the Prevention of Contrast-induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention
This is a multicenter, randomized, open-label phase II clinical trial to evaluate alprostadil liposomal injection in the prevention of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention.
Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran of Phase II Clinical Trial
This is a randomized, positive-control, multicenter, multiple-dose, dose-escalation phase II trial
The Safety, Tolerability and Pharmacokinetic Phrase I Study of Alprostadil Fat Emulsiom Injection in Healthy Adult Volunteers
Conducted in Chinese healthy adult volunteers,the study aims to observe the safety, tolerability and pharmacokinetic of single-dose administration of different doses of Alprostadil Liposome for Injection as well as to confirm the safety dose range.
100 Clinical Results associated with Alprostadil liposome(CSPC Zhongqi)
100 Translational Medicine associated with Alprostadil liposome(CSPC Zhongqi)
100 Patents (Medical) associated with Alprostadil liposome(CSPC Zhongqi)
100 Deals associated with Alprostadil liposome(CSPC Zhongqi)